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BACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with
hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities
while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting
dose impacts on OS or toxicity experienced by the elderly.
METHODS: In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while
accounting for common prognostic factors and demographic characteristics in univariable and multivariable models.
RESULTS: Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were
more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference
in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93–1.08), p= 0.97).
There was no relationship between starting dose of sorafenib 800 mg vs 400mg/200mg and OS between those <75 and ≥75 years.
The elderly experienced a similar overall incidence of grade 2–4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%,
p= 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary
between different starting doses of sorafenib.
CONCLUSIONS: Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib
prescribed.
British Journal of Cancer (2021) 124:407–413; https://doi.org/10.1038/s41416-020-01116-9
BACKGROUND
Hepatocellular carcinoma (HCC) is a leading cause of cancer death
with >850,000 cases diagnosed yearly worldwide with a similar
annual mortality.1 If HCC presents at an early stage, curative
options such as liver transplantation, resection or percutaneous
radiofrequency ablation are feasible; however, this is only possible
in 30–40% of patients with the majority undergoing non-curative
treatments such as transcatheter arterial chemoembolisation or
systemic treatment.2
Sorafenib is a multi-kinase inhibitor that interferes with
intracellular and extracellular signalling pathways associated with
tumour angiogenesis and tumour proliferation, including vascular
endothelial growth factor receptors, platelet-derived growth factor
receptor and RAF/mitogen-activated protein kinase.3 The SHARP
and Asia-Pacific studies confirmed overall survival (OS) benefit of
sorafenib over placebo; however, the median age of patients in
both studies was <65 years.4,5
Age is a risk factor for developing HCC with the highest age-
specific incidence in most Western populations occurring over 75
years, a pattern that is replicated in Asia.6–8 The number of elderly
patients with HCC is likely to increase not only as a result of
demographic trends but also due to improvements in treatment
of chronic liver disease. Comorbidities and frailty in the elderly
often makes them unsuitable for surgical and locoregional
treatment—placing even more importance on clear guidelines
for medical therapy. The safety of sorafenib treatment in elderly
patients is of particular concern due to comorbidities, impaired
organ function, polypharmacy as well as altered pharmacokinetics;
sorafenib is metabolised by CYP3A, the activity of which slows
with increasing age.9 There is a paucity of evidence in terms of
safety, efficacy and recommended dosing for the elderly due to
their under-representation in clinical trials. It has been suggested
that the clinical outcome from sorafenib is not influenced by
increasing age.9–13 In a multicentre study in Japan, 179 patients
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aged ≥75 years receiving sorafenib were matched to 279 patients
aged <75 years.14 No difference in efficacy or tolerability was
reported. Conversely, Edeline et al. and Williet et al. reported a
greater discontinuation rate due to toxicity among older popula-
tions and greater incidence of serious adverse events (AEs) in the
latter.15,16 Real-world studies illustrate that patients aged >70
years are more likely to be started on 200/400 mg daily as
opposed to standard dosing with 800 mg/daily.14,17,18 Two studies
found that sorafenib was better tolerated in the elderly when
physicians commenced on a reduced initial dose but there
remains a lack of consensus on initial dose of sorafenib among
elderly patients.19,20 To our knowledge, previous studies evaluat-
ing treatment of HCC with sorafenib in an elderly population have
been based on a single geographical region. There is a clear need
for international data as the differing aetiology of HCC globally
can impact on outcomes of treatment.12
To address this issue and to overcome the limitations of
previous studies, we designed a large collaborative global study
with the primary objective to assess the effect of age on OS in
patients treated with sorafenib while accounting for common
prognostic factors. As a secondary endpoint, we investigated the
impact of the starting dose of sorafenib in the elderly population
aged ≥75 years on OS and drug tolerability.
METHODS
Five thousand five hundred and ninety-eight consecutive patients
who had undergone treatment with sorafenib from 2007 to 2018
were recruited from seven centres: Veterans Health Administration
(VHA) Hospitals, USA (4903 patients, 87.6%); Kinki University
School of Medicine, Japan (194 patients, 3.5%); Humanitas Clinical
and Research Centre, Milan, Italy (168 patients, 3.0%); Imperial
College NHS Healthcare Trust, UK (113 patients, 2%); University
Medical Centre Freiburg, Germany (71 patients, 1.3%); National
Cancer Centre Hospital, South Korea (97 patients, 1.7%); and
Università degli Studi del Piemonte Orientale, Novara, Italy (52
patients, 0.9%). We accessed prospectively collected cohorts of
patients who had a diagnosis of HCC, except from the VHA
hospitals, where data were retrospectively collected. Consecutive
patient data were collected as part of routine clinical care. For
prospective collection, patients were either Child–Turcotte–Pugh
(CTP) grade A liver impairment or CTP B with low disease burden.
The VHA cohort included patients of all CTP liver classes. All
patients were discussed at a multidisciplinary team meeting,
where they were deemed not suitable for curative or locoregional
treatment. No patients had previous systemic therapy. Patients
were either started on 200 or 400mg once daily or 400 mg twice
daily (800 mg/day), depending on clinical assessment. Treatment
with sorafenib continued until significant toxicity from treatment,
withdrawal of consent or disease progression.
Toxicity related to sorafenib, including hand–foot skin reaction
(HFSR), diarrhoea, liver dysfunction, mucositis, rash, constipation,
anorexia, fatigue and hypertension, was evaluated using the
National Cancer Institute Common Terminology Criteria for
Adverse Events 4.03. Information on whether further dose
reductions were required was obtained. OS was taken from the
date of sorafenib commencement to the date of progression,
death on treatment or last follow-up. The study protocol was
approved by the institutional review board or ethics committee in
each participating institution and was conducted in accordance
with the Declaration of Helsinki (update 2004).
Statistical analysis
The primary endpoint was OS comparing patients aged <75 and
≥75 years. Secondary outcomes were the incidence of AEs and the
impact of dose on incidence of AEs and OS. Continuous variables
were expressed as median. Categorical variables were expressed
as frequencies with percentages. Variables were compared
between younger (<75 years) and the elderly (≥75 years) using
Mann–Whitney U test for continuous variables and χ2 test or
Fisher’s exact test for categorical variables, as appropriate. Other
prognostic variables considered were BCLC stage (AB vs CD), AFP
(≤ or >400 ng/dL), tumour size (≤ or >7 cm), aetiology of liver
disease, presence of portal vein thrombosis (PVT), sorafenib
starting dose (800mg vs 200/400mg), presence of metastases
and country of origin. The survival function by age and potential
prognostic factors was plotted using Kaplan–Meier curves with
differences between these groups compared using log-rank test.
Before conducting Cox regression analyses, the proportional
hazards assumption was checked with log-likelihood ratio tests
of each predictor over time bands. There was no evidence of
violation of the proportional hazard assumption for the main
predictor (age; p= 0.81). For the predictors for which the
proportional hazards assumption did not hold, time-dependent
effects were explicitly accounted for by adding interaction terms
with time bands in all regression analyses.21
Due to the considerable proportion of missing data for some
variables (up to ~90% for the full data set of 5598 patients and up
to ~70% for the subset of 792 patients with age ≥75 years), a
multiple imputation with chained equations (MICE) approach was
used, assuming that the data were missing at random. Each data
set was imputed separately to allow for imputation of prognostic
factor specific to elderly patients. For both the full data set of 5598
patients and the subset of 792 elderly patients, we included in the
imputation models (i) all predictors of missingness (log-likelihood
p < 0.10) for any of the variables included in the initial analysis
model specified above, (ii) the event indicator (subject alive/
death), and (iii) the Nelson–Aalen estimator of baseline hazard.22
From each original data set, we generated 100 imputed data sets
to provide stable estimates. Diagnostic plots of trace lines
revealed satisfactory convergence of imputation models. Plots of
imputed values vs the observed values suggested that imputed
values were plausible.
All p values were derived from two-tailed tests, and p < 0.05 was
defined as statistically significant. All statistical analysis was
conducted using SPSS statistical package version 26 (SPSS Inc.,
Chicago, IL, USA) and R version 3.61 (Copyright 2019 The R
Foundation for Statistical Computing) with packages mice 3.7.0
and survival 3.1–8.
RESULTS
Baseline characteristics of the study population
Five thousand five hundred and ninety-eight patients were
included. Of these, 792 (14.1%) were equal to or over the age of
75 years (Table 1). The mean age of the study population was 64.3
years. The seven centres had different distributions of ages, with
the Korean centre almost exclusively treating patients aged <75
years (97.9%). The majority of the study population were men
(96.5%) and had CTP A stage liver cirrhosis (58.9%). Hepatitis C
virus (HCV) infection and alcohol misuse were the primary
underlying causes of liver disease (51.7 and 46.0%, respectively),
although several patients had multiple aetiological factors.
Three thousand five hundred and three patients (62.6%) were
started on sorafenib 800mg/day and 2083 (37.2%) received a
reduced dose of 400mg/day, with a median follow-up time of
15.2 months. Twelve patients (0.2%) received 200 mg/day. The
proportion of patients in the two dosing groups varied
significantly by centre (p > 0.001). Patients from Milan, Korea,
USA and Japan were mostly on standard dose sorafenib (100, 89.7,
63.1 and 54.1%, respectively), whereas those in the UK, Germany
and Novara were largely on reduced dose (82.3, 77.5 and 75.0%,
respectively). The median duration of sorafenib treatment was
5.0 months (range 0.03–83.6 months). Progressive disease was the
main cause of sorafenib cessation (56.0%) followed by toxicity
(20.6%). Overall sorafenib was well tolerated; the most common
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severe (grade ≥2) AEs experienced were fatigue and diarrhoea,
occurring in 15.2 and 17.3% of all patients, respectively.
Age is not a significant prognostic factor with sorafenib
Five thousand and fifty-four patients (90.3%) died during follow-
up and median OS for the cohort was 7.3 months (95% confidence
interval (CI): 7.0–7.6). OS in patients aged ≥75 years did not
deviate significantly from those aged <75 years (7.3 months, 95%
CI: 7.0–7.6 vs 7.2 months, 95% CI: 6.4–8.0, p= 0.95) (Fig. 1). OS did
differ significantly across the treatment centres with the longest
median OS reported in Japanese, 14.3 months (95% CI: 9.2–19.4)
and the shortest OS in South Korea, 5.8 months (95% CI: 4.4–7.2)
(p= 0.01).
After adjustment for common prognostic factors and multiple
imputation of missing data, the effect of age on survival remained
negligible (hazard ratio (HR), 1.03 (95% CI: 0.95–1.12), p= 0.5).
Similarly, starting dose had no impact on OS (HR 0.96, 95% CI
0.91–1.02, p= 0.3). Prognostic factors independently associated
Table 1. Baseline characteristics of the study population.
Baseline characteristic All patients (%), N= 5598 Age <75 (%), N= 4806 (85.8) Age ≥75 (%), N= 792 (14.1) p value
Centre <0.01
USA 4903 (87.6) 4318 (89.8) 585 (73.8)
Japan 194 (3.5) 108 (2.2) 86 (10.9)
Milan, Italy 168 (3.0) 120 (2.5) 48 (6.1)
UK 113 (2.0) 81 (1.7) 32 (4.0)
South Korea 97 (1.7) 95 (2.0) 2 (0.3)
Germany 71 (1.3) 53 (1.1) 18 (2.3)
Novara, Italy 52 (0.9) 31 (0.6) 21 (2.6)
Sex <0.01
Male 5402 (96.5) 4667 (97.1) 735 (92.7)
Female 196 (3.5) 139 (2.9) 57 (7.2)
Risk factors for chronic liver diseasea
Hepatitis B infection 395 (7.1) 366 (7.6) 29 (3.7) <0.01
Alcohol relatedb 2368 (43.8) 2244 (47.8) 124 (17.6) <0.01
Hepatitis C infection 2896 (51.7) 2722 (56.6) 174 (22.0) <0.01
Otherc 237 (4.3) 156 (3.3) 81 (10.3) <0.01
Child–Turcotte–Pugh class <0.01
A 3281 (58.9) 2754 (57.5) 527 (67.0)
B 2071 (37.2) 1821 (38.0) 250 (31.8)
C 220 (3.9) 211 (4.4) 9 (1.1)
Maximum tumour diameter <0.01
≤7 cm 2236 (66.1) 1914 (67.0) 322 (60.9)
>7 cm 1148 (33.9) 942 (33.0) 206 (39.0)
Portal vein thrombus <0.01
Absent 3633 (71.6) 3070 (70.6) 563 (77.9)
Present 1441 (28.4) 1281 (29.4) 161 (22.1)
AFP (ng/dL) 0.05
≤400 2523 (47.9) 2160 (47.4) 363 (51.5)
>400 2743 (52.1) 2401 (52.6) 342 (48.5)
Metastases 0.3
Absent 4381 (79.0) 3778 (79.2) 603 (77.5)
Present 1168 (21.0) 993 (20.8) 175 (22.5)
Previous treatment
Resectiond 125 (18.0) 98 (20.1) 27 (13.0) 0.03
Radiofrequency ablation 394 (7.0) 319 (81.0) 75 (19.0) <0.01
Transarterial chemoembolisation 792 (14.1) 231 (14.6) 561 (14.0) 0.55
Y90 5 (0.1) 5 (0.1) 0 (0.0) 0.41
Starting dose of sorafenib 0.40
200/400mg 2095 (37.4) 1788 (37.2) 307 (38.8)
800mg 3503 (62.6) 3018 (62.8) 485 (61.2)
AFP α-fetoprotein.
aSome patients often had overlapping aetiological risk factors.
bAlcohol data missing for Japanese patients (N= 194).
cOther aetiology data missing for Korean patients (N= 97).
dResection data missing for US patients (N= 4903).
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with OS were BCLC stage, CTP class, AFP, tumour size, presence of
extrahepatic disease and geographical origin (Table 2). As
expected, the adjusted effects were similar in size and direction
to the complete case analysis (Supplementary Table 1), with
multiple imputation analyses achieving greater precision.
Prognostic factors of OS in the elderly
Of the patients aged ≥75 years, the mean age was 79.8 years
(range: 75.0–93.0). Elderly patients were less likely to have HCV
and hepatitis B virus (HBV) or have consumed excess alcohol (p <
0.001, Table 1). They also had lower AFP at diagnosis (p= 0.049)
and less PVT compared to those aged <75 years (22.1 vs 29.4%, p
< 0.001) but were more likely to have larger tumours (39.0 vs
33.0%, p= 0.007). There were fewer elderly patients with
advanced CTP B and CTP C cirrhosis compared to the younger
population (31.8 vs 38.0% and 1.1 vs 4.4%, respectively, p < 0.01).
The starting dose of sorafenib did not have an impact on OS in the
elderly; the median OS for the full-dose sorafenib group was
7.4 months (95% CI: 6.0–8.8) and 7.1 months (95% CI:
6.2–7.9 months) with a reduced starting dose (p= 0.40), (Fig. 2).
Other independent prognostic identified were CTP class, AFP,
tumour size and underlying disease aetiology (Table 2).
Sorafenib-related AEs in the elderly
The incidence of grade 2–4 toxicities was similar between both
age groups (63.5 vs 56.7%, p= 0.11, Table 3). Regarding specific
AEs, the older age group had a significantly greater incidence of
anorexia (14.0 vs 7.2%, p < 0.01) and grade ≥2 rash (6.3 vs 3.1%,
p= 0.048) compared with the younger group. When considering
the relationship between the different starting doses and
incidence of toxicities in the elderly population, no difference in
the incidence grade ≥2 toxicities was observed in either 800mg or
reduced dose sorafenib groups (p= 0.13).
More elderly patients discontinued treatment as a result of
toxicity, compared to the younger patients (27.0 vs 21.6%, p=
0.001, Fig. 3) and this did not vary between different starting
doses of sorafenib. The mean duration of treatment was similar
between those aged over and under 75 years (p= 0.071), and
again, the starting dose of sorafenib did not affect treatment
duration in the elderly (p= 0.25). There were no differences
between the age groups in the proportion of early treatment
cessation at 28 days (p= 0.52).
DISCUSSION
The peak incidence of HCC occurs over the age of 75 years and yet
this population group is underrepresented in clinical trials
resulting in uncertainty regarding the safety and efficacy of
sorafenib. As a result, clinicians extrapolate data from younger
patients to the older patient group often leading to empiric
dosing.4,5,9,23 There is a tendency to commence elderly patients on
a lower starting dose of sorafenib with the aim to obviate toxicity
in order to maximise duration of therapy and survival benefit.
However, there is conflicting evidence for this practice and no
consensus on the recommended starting dose.10,14,16,19,20,24 We
have conducted the largest international study investigating the
impact of sorafenib dosing in an elderly population, comparing
clinical outcomes to patients aged <75 years.
We have conclusively shown that median OS in the elderly is
the same as that in a younger patient population, regardless of
dose administered. This in line with a number of smaller studies
carried out in Europe and Asia; the strength of this study being
that we have considered patients from Asia, Europe and the USA
ensuring global representation of aetiologies of HCC and differing
prescribing practices.10,14,15,19,25,26 While combination therapy is
likely to be the new gold standard for the management of HCC,
given the relative cost of sorafenib, it is unlikely that many health
systems will adopt this immediately and instead will continue to
utilise sorafenib.
Our study emphasises the importance of tumour-related factors
and hepatic reserve in influencing survival in both the entire
population studied and in those ≥75 years confirming that CTP
class, tumour size and serum AFP are independent prognostic
factors. Of note, the younger population was more likely to have
HBV-related HCC, a more aggressive phenotype.27,28 Interestingly,
there are clear differences in international prescribing practices in
that no patient from Korea were treated with low-dose sorafenib,
differences which we have highlighted in our previous studies.29
Of importance, the starting dose of sorafenib was not an
independent predictor of OS confirming the results of the
previously published work by Kaplan and colleagues, which is
further strengthened in this paper by the inclusion of patients
from other global regions.30 We also report similar frequency and
severity of toxicity between the two age groups, which again
reaffirms the data previously published and is in line with the
incidence of toxicities reported in the SHARP and Asia-Pacific
trials.10 The only differences of note were anorexia and rash, which
was more pronounced in the elderly cohort, a key concern in
maintaining quality of life in the elderly.
There is a complicated relationship between sorafenib dosing
and toxicity, where toxicity is not only associated with improved
outcome but also necessitates dose reductions such that, even in
those patients requiring drug cessation from toxicity, the survival
benefit continues beyond the drug administration period.13,29,31
Although this was not an endpoint of the study, we confirmed the
findings of Iavarone and colleagues, in that discontinuation due to
toxicity, even in the elderly, was associated with improved OS
(Supplementary Fig. 1). The explanation for this remains to be
ascertained with some groups proposing immune-modulating
effects of sorafenib, resulting in T cell activation and infiltration of
the tumour.32 A limitation of this study was that only starting dose
was reported and not subsequent dose reductions or cumulative
dose, which has been shown to impact on both duration of
therapy and survival.13 A recent study by Tovoli and colleagues
illustrates that tailoring dosing to the individual patient according
to AEs experienced results in a longer duration of treatment,
higher cumulative dose and an improved OS.33 We observed a
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Fig. 1 Kaplan–Meier estimates of overall survival according to
age. The curves illustrate the prognostic relationship of age (<75
and ≥75 years) with overall survival in patients receiving sorafenib
for HCC.
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elderly patients despite no difference in the overall incidence of
AEs reported. This is mirrored by an analysis of the Celestial study
by age, which confirms higher discontinuation rates in the elderly,
again with no differences in toxicity.34 This may reflect physicians’
attitudes whereby they may be more inclined to stop treatment in
the elderly even when faced with a similar safety profile as in a
younger population.35
Chronologic age alone does not provide sufficient information
on an individual’s ability to tolerate anticancer therapy, and in
patients of the same age, there is wide heterogeneity in their
ability to undergo therapy as a result of comorbidities, con-
comitant medications, altered physiologic reserve and social
support. The National Comprehensive Cancer Network and the
Table 2. Effects of age and common prognostic factors on overall survival in multiple imputed data sets.
Predictor Univariable models Multivariable models
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Full sample set of patients with HCC (n= 5598)
Age ≥75 years 1.00 (0.93–1.08) 0.9 1.03 (0.95–1.12) 0.5
BCLC stage C or D vs 0, A or B 2.04 (1.88–2.22) <0.001 1.57 (1.43–1.73) <0.001
CTP class (B, C vs A) 2.28 (2.13–2.44) <0.001 2.15 (2.01–2.30) <0.001
Tumour size >7 cm 1.80 (1.63–1.98) <0.001 1.57 (1.43–1.73) <0.001
PVT 1.05 (0.98–1.12) 0.1 1.02 (0.96–1.09) 0.5
Presence of metastasis 1.50 (1.37–1.64) <0.001 1.20 (1.08–1.32) <0.001
AFP > 400 ng/dL 1.88 (1.74–2.04) <0.001 1.70 (1.57–1.85) <0.001
HCV vs other aetiologies 0.86 (0.82–0.91) <0.001 0.88 (0.83–0.94) <0.001
Starting dose (800mg vs 200/400mg) 0.94 (0.89–1.00) 0.05 0.96 (0.91–1.02) 0.29
Continent (Asia vs USA/Europe) 0.74 (0.64–0.85) <0.001 0.78 (0.67–0.89) <0.001
Patients aged >75 years with HCC (n= 792)
BCLC stage C or D vs 0, A or B 1.50 (1.28–1.76) <0.001 1.19 (0.98–1.45) 0.08
CTP class (B, C vs A) 2.35 (1.91–2.89) <0.001 2.23 (1.81–2.76) <0.001
Tumour size >7 cm 1.56 (1.30–1.87) <0.001 1.37 (1.13–1.65) <0.01
PVT 1.20 (1.00–1.44) 0.05 1.08 (0.90–1.30) 0.4
Presence of metastasis 1.39 (1.16–1.65) <0.01 1.13 (0.91–1.39) 0.3
AFP > 400 ng/dL 1.70 (1.37–2.10) <0.001 1.56 (1.26–1.95) <0.001
HCV vs other aetiologies 0.65 (0.54–0.79) <0.001 0.70 (0.58–0.86) <0.001
Starting dose (800mg vs 200/400mg) 1.07 (0.92–1.25) 0.3823 0.95 (0.82–1.12) 0.5671
Continent (Asia vs USA/Europe) 0.60 (0.45–0.79) <0.001 0.80 (0.60–1.07) 0.1334
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Fig. 2 Kaplan–Meier estimates of overall survival according to
starting dose of sorafenib received. Curves illustrate the prognostic
relationship of starting dose (800mg vs reduced dose) with overall
survival in patients aged ≥75 years receiving sorafenib for HCC.
Table 3. Incidence of adverse events (NCT CTCAE v 4.0 grade 0–1 and
grade 2–4) between age groups.
Adverse event AEs in <75 years,
n (%)
AEs in ≥75 years,
n (%)
p value
Grade <2 Grade ≥2 Grade <2 Grade ≥2
HFSR 424 (87.4) 61 (12.6) 175 (84.5) 32 (15.5) 0.31
Rash 473 (96.9) 15 (3.1) 194 (93.7) 13 (6.3) 0.048
Mucositis 474 (97.1) 14 (2.9) 200 (96.6) 7 (3.4) 0.72
Hypertension 451 (92.4) 37 (7.6) 183 (88.4) 24 (11.6) 0.17
Anorexia 453 (92.8) 35 (7.2) 178 (86.0) 29 (14.0) <0.01
Fatigue 405 (83.0) 83 (17.0) 170 (82.1) 37 (17.9) 0.78
Diarrhoea 415 (85.0) 73 (15.0) 173 (83.6) 34 (16.3) 0.62
Constipation 484 (99.2) 4 (0.8) 204 (98.6) 3 (1.4) 0.45
Liver
dysfunction
425 (93.2) 31 (6.8) 184 (94.8) 10 (5.2) 0.43
Other 304 (79.2) 80 (20.8) 105 (82.0) 23 (18.0) 0.48
Any adverse
event grade ≥2
247 (56.7) 120 (63.5) 0.111
HFSR hand–foot skin reaction.
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International Society of Geriatric Oncology recommend the
implementation of comprehensive geriatric assessments in clinical
practice to provide detailed evaluation of the health status of an
older adult. The use of these tools has been shown to highlight
areas of vulnerability, reduce toxicity, improve quality of life and
improve prognostication in the elderly.36 Importantly, the use of
geriatric assessments assist in treatment decision-making such
that studies investigating their use illustrate treatment optimisa-
tion in up to 50% of elderly patients.37
The lack of clinical trial data in the elderly has long been
recognised but only recently has been addressed by funding
bodies such that the Food and Drug Administration and National
Institutes of Health have introduced guidelines regarding trial
inclusion criteria and there is a move to restrict funding for grants
that have an upper age limit.38,39 These developments will
enhance our knowledge of therapeutic efficacy of medications
in the elderly.
Our study was broad in its criteria for enrolment and is thus a
fair reflection of global clinical practice. Patients of various
aetiologies, ages and stages of liver disease were included. The
median OS in our study is lower compared to the SHARP and Asia-
Pacific publications.4,5 This can be attributed to the inclusion of a
significant number of patients with CTP B and C liver dysfunction
(39%), and a significant difference was observed in the median OS
between each CTP class (median OS CTPA/B/C—10.1/4.7/
1.7months). The overall median OS presented in our study is in
line with a meta-analysis by McNamara and colleagues who
investigated the benefit of sorafenib across CTP status and
reported a similar OS of 7.2 months.40 Patients were enrolled
consecutively in all centres as to reduce selection bias. Since all
centres were tertiary referral centres, the study benefitted from
physician expertise. Nonetheless, there are several limitations to
our study, and selection bias must be considered when evaluating
our results particularly given the differences in prescribing practice
across centres. Other limitations include no quantification of
overall drug dose administered and the impact of dose reductions
on outcome and the retrospective nature of some aspects of the
data collection particularly AE reporting. The issue of missing data
was addressed using multiple imputation, an approach that relies
on the assumption that the data are missing at random; that is,
that the missing data mechanism does not depend on unob-
served data. Given the large samples size and the amount of
information available in the data set, this allowed us to include in
the imputation models all variables associated with missing data,
rendering the missing-at-random assumption likely to hold.
CONCLUSION
This large international cohort study shows that patients aged ≥75
years with HCC have an equivalent OS benefit with sorafenib to
younger patients, regardless of the starting dose. We show that
the overall toxicity rates in the elderly are equivalent to those
aged <75 years, and the incidence and grade of toxicity
experienced was independent of treatment dose received. This
study highlights the importance of considering sorafenib treat-
ment in the elderly on an individual basis as a viable treatment
option.
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Fig. 3 Pie charts demonstrating the reasons for sorafenib discontinuation. Reasons for discontinuation are demonstrated in patients aged
≥75 years (left) and aged <75 years (right) according to death, disease progression, toxicity or other.
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